Cytochrome P450 3A4 is the target of small molecular inhibitors like ritonavir18 that are used to increase bioavailability of antiretroviral treatments for human immunodeficiency virus or coronavirus disease 2019 with increased triglyceride levels being a reported side effect19. This evidence concerns the gene CYP3A4 and COVID-19.